Second, our prediction model has high specificity (93.8%) and moderate sensitivity (76.8%), which may help to identify HCC patients who are not suitable for GPC-3-targeted immunotherapy in the future, but whether this model can be combined with other indicators to improve its sensitivity without impairing specificity in predicting GPC-3 expression warrants further research. This evidence concerns the gene GPC3 and hepatocellular carcinoma.